The U.S. Food and Drug Administration is investigating a potential tumor risk associated with Novartis's gene therapy Zolgensma after the company reported new cases of tumors in children who received the treatment · Azimuth Daily
The U.S. Food and Drug Administration is investigating a potential tumor risk associated with Novartis's gene therapy Zolgensma after the company reported new cases of tumors in children who received the treatment.
Items older than 7 days — their verdicts, sources and coverage history — are part of the Azimuth Daily record and available to signed-in readers.